Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Canada proposes nicotine patch switch

This article was originally published in The Tan Sheet

Executive Summary

Canada proposes nicotine patch switch: Health Canada Therapeutic Products Programme proposes switch of transdermal nicotine patches with delivery rates of 22 mg/day and less to nonprescription status in a regulatory amendment published in the July 19 Canada Gazette, Part I. Rx patches are marketed in Canada by Novartis, Hoechst Marion Roussel, Boerhinger Ingelheim and McNeil. TPP intends to proceed directly to the Canada Gazette, Part II if favorable comments are received, thereby quickening the switch process. OTC nicotine chewing gum in a 4 mg strength will be available "shortly," the notice states...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel